Invega
Paliperidone
Invega
Invega is an atypical antipsychotic medication prescribed to treat patients with schizophrenia.
The most common side effects of Invega are:
- Restlessness
- Involuntary movements or facial tics
- Tremors
- Muscle stiffness
- Nausea
- Weight gain
For more information, see our Invega side effects page.
Invega is a medication prescribed to treat patients with schizophrenia who experience symptoms of social withdrawal, apathy, emotional unresponsiveness, hallucinations, delusions, agitation, and disorganized thinking.
Other medications may interact with Invega or increase the risk of side effects. Discuss any medications, supplements, or vitamins with your doctor before taking Invega.
The following medications may interact with Invega:
- Erythromycin
- Gatifloxacin
- Moxifloxacin
- Sparfloxacin
- Antipsychotics
- Cisapride
- Levodopa
- Anxiety medications
- High blood pressure medications
- Seizure medications
- Disopyramide
- Dofetilide
- Procainamide
- Quinidine
- Sotalol
- Sedatives
- Sleeping pills
- Tranquilizers
Patients with a history or current diagnosis of any of the following conditions should consult their doctor before beginning treatment with Invega:
- Alzheimer’s disease
- Dehydration
- Heart problems
- Hypotension
- Hypovolemia
- Stroke
- Difficulty swallowing
- Cancer
- Blood or bone marrow problems
- Diabetes
- Hyperglycemia
- High blood prolaction
- Meuroleptic malignant syndrome
- Parkinson’s disease
- Priapism (painful or prolonged erections)
- Seizures
- Stomach/bowel problems
- Brain tumor
- Kidney disease
- Liver disease
This is not a complete list of possible Invega interactions. Consult your doctor about any possible interactions with this medicine.
Typical Dosage Recommendations
Patients should take Invega exactly as prescribed by a doctor, as dosage recommendations differ for the treatment of various conditions.
Invega is distributed as an extended release tablet intended for daily use and doses range from 1.5 mg to 9 mg. Swallow Invega whole, do not split, chew, or crush.
The casing of Invega may pass into your stool after your body has absorbed the medicine. This is normal.
Missing a Dose of Invega
If you miss a dose of Invega, take it as soon as you remember. If you are close to your next dose, skip the missed dose and resume your normal dosage schedule. Do not take a double dose of this medicine.
Invega Overdose
Call your doctor immediately if you believe you are experiencing any of the following overdose symptoms:
- Involuntary body movement
- Muscle stiffness
- Restlessness
- Unsteadiness
- Drowsiness
- Palpitations
December 19, 2006
Invega carries a Black Box warning for elderly patients with dementia. These patients should not take Invega because of an increased risk of fatality. Older patients with dementia who take Invega may have a greater chance of having a stroke during treatment.
Invega was recalled in November 2009 when one lot of Invega 6 mg tablets were coated in pink, when the approved color for the 6 mg tablets was beige. (Recall # D-030-2010).
Other Warnings
Neuroleptic Malignant Syndrome (NMS) is a potentially fatal side effect of Invega. Patients should call their doctor immediately if they have symptoms of high fever, stiff muscles, shaking, confusion, sweating, changes in pulse, and heart rate. These are all potential symptoms for NMS.
Tardive Dyskinesia (TD), a condition that causes uncontrollable movement of the face, tongue, and other body parts, is a serious and sometimes permanent side effect of Invega. Chances of developing TD increase as treatment with Invega is extended over time.
Invega may raise your blood sugar levels. Patients, who have diabetes or risk factors for developing diabetes, should consult their doctor before beginning treatment with Invega.
Invega may raise levels of prolactin in the blood, causing a condition called hyperprolactinemia. This may stop menstrual periods and hinder milk production in women, cause men to develop breasts or prevent men from developing an erection.
-
March 5, 2010, 9:38 am
-
March 4, 2010, 9:08 am
-
March 2, 2010, 5:46 pm
-
March 1, 2010, 1:00 pm


